Cite
MLA Citation
Jorge E Cortes et al.. “Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.” Lancet, vol. 3, no. 12, 2016, pp. e581–e591. http://access.bl.uk/ark:/81055/vdc_100039326611.0x000009